Drugs / Etigilimab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03119428 | May 2017 → May 2019 | cancer of unknown primary site, metastatic malignant neoplasm | OncoMed Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04761198 | Mar 2021 → Oct 2023 | cancer, metastatic neoplasm | Mereo BioPharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05715216 | Oct 2021 → Apr 2025 overdue | ovarian cancer | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2022-09-12 | Mereo BioPharma | Results Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors mereobiopharma.com ↗
Key updates: Cervical cancer : 3/7 PD-L1 combined positive score CPS>1%, CPI-naïve cervical cancer subjects with confirmed complete responses (cCRs) ORR of 43%, 2 ongoing at >284 days and >142 days, and 1 withdrew consent with ongoing cCR at 163 days. |
| 2022-06-02 | Mereo BioPharma | Results Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan mereobiopharma.com ↗
Additionally, 7 subjects with clinical benefit remained on study treatment for ≥ 18 weeks. |
| 2022-05-26 | Mereo BioPharma | Results Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting mereobiopharma.com ↗
At the time of the February 10, ASCO abstract deadline, of the 27 efficacy-evaluable subjects with minimum of 1 staging scan or radiological/clinical progression, 12 subjects had a clinical benefit with 1 CR, 2 PRs and 9 SDs and 15 subjects had radi |
| 2021-11-30 | Mereo BioPharma | Results Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors mereobiopharma.com ↗
We are particularly excited by the complete response in the cervical cancer cohort and the partial response in one of the ovarian cancer patients treated to-date. |
| 2019-10-19 | Mereo BioPharma | Regulatory Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT) mereobiopharma.com ↗
today announced that the U.S. Food and Drug Administration has cleared an investigational new drug (IND) application to proceed with a Phase 1b/2 study for the Company’s lead oncology product candidate etigilimab. |
All press releases naming this drug 7 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Etigilimab | “anti-TIGIT antibody etigilimab alone” PMID 34844977 ↗ Mar 2022 |
| Known as | OMP-313M32 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298205 ↗ |
| Action | Inhibit | “T-cell immunoreceptor with Ig and ITIM domains inhibitor” CHEMBL4298205 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4298205 ↗ |
| Route | Intravenous | “IV infusion of IV etigilimab every 2 weeks” NCT04761198 ↗ |
| Target | TIGIT | “T-cell immunoreceptor with Ig and ITIM domains inhibitor” CHEMBL4298205 ↗ |